SG11201603134XA - Mutated fibroblast growth factor (fgf) 1 and methods of use - Google Patents

Mutated fibroblast growth factor (fgf) 1 and methods of use

Info

Publication number
SG11201603134XA
SG11201603134XA SG11201603134XA SG11201603134XA SG11201603134XA SG 11201603134X A SG11201603134X A SG 11201603134XA SG 11201603134X A SG11201603134X A SG 11201603134XA SG 11201603134X A SG11201603134X A SG 11201603134XA SG 11201603134X A SG11201603134X A SG 11201603134XA
Authority
SG
Singapore
Prior art keywords
fgf
methods
growth factor
fibroblast growth
mutated
Prior art date
Application number
SG11201603134XA
Other languages
English (en)
Inventor
Jae Myoung Suh
Michael Downes
Ronald M Evans
Annette Atkins
Ruth Yu
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of SG11201603134XA publication Critical patent/SG11201603134XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
SG11201603134XA 2013-10-21 2014-10-21 Mutated fibroblast growth factor (fgf) 1 and methods of use SG11201603134XA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361893766P 2013-10-21 2013-10-21
US201461949945P 2014-03-07 2014-03-07
US201461975530P 2014-04-04 2014-04-04
US201462019185P 2014-06-30 2014-06-30
US201462046038P 2014-09-04 2014-09-04
PCT/US2014/061638 WO2015061361A1 (en) 2013-10-21 2014-10-21 Mutated fibroblast growth factor (fgf) 1 and methods of use

Publications (1)

Publication Number Publication Date
SG11201603134XA true SG11201603134XA (en) 2016-05-30

Family

ID=52826689

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603134XA SG11201603134XA (en) 2013-10-21 2014-10-21 Mutated fibroblast growth factor (fgf) 1 and methods of use

Country Status (9)

Country Link
US (3) US9925241B2 (de)
EP (1) EP3060238A4 (de)
JP (1) JP6621752B2 (de)
CN (1) CN105828833A (de)
AU (2) AU2014340241B2 (de)
CA (1) CA2928135A1 (de)
MX (1) MX2016005101A (de)
SG (1) SG11201603134XA (de)
WO (1) WO2015061361A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP2938740B1 (de) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Chimäre fgf19 peptide zur verwendung in der behandlung von gallensäureerkrankungen
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
MX2016005101A (es) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (de) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Verfahren und verwendungen zur modulierung von gallensäurehomöostase und behandlung von gallensäurestörungen und -erkrankungen
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2017075260A1 (en) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
EP3436608A4 (de) * 2016-03-28 2019-12-04 Trefoil Therapeutics, Inc. Modifizierte fibroblastenwachstumsfaktoren und verwendungen davon
US10385113B2 (en) 2016-03-30 2019-08-20 The Board Of Trustees Of The University Of Arkansas Engineered FGF compositions and methods of use thereof
WO2018018010A1 (en) * 2016-07-21 2018-01-25 Metacrine, Inc. Fgf mutants and uses thereof
EP3491011A1 (de) * 2016-08-01 2019-06-05 Salk Institute for Biological Studies Fibroblastenwachstumsfaktor (fgf) 1-proteine mit fähigkeit zur senkung des glucosespiegels und mit reduzierter mitogenizität
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106957359B (zh) * 2016-08-31 2020-04-24 黄志锋 Fgf1突变体及其医药应用
WO2018112200A1 (en) * 2016-12-15 2018-06-21 Salk Institute For Biological Studies Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
EP3615560A4 (de) 2017-04-26 2020-12-23 University of Cincinnati Zusammensetzungen von fibroblastenwachstumsfaktorliganden und verfahren zur behandlung von patienten mit ischämie-reperfusionstherapie
EP3619324A4 (de) 2017-05-05 2020-12-30 Trefoil Therapeutics, Inc. Rekombinante modifizierte fibroblasten-wachstumsfaktoren und therapeutische verwendungen davon
US11267855B2 (en) 2018-03-16 2022-03-08 The Board Of Trustees Of The University Of Arkansas Engineered FGF1 and FGF2 compositions and methods of use thereof
CN113727996B (zh) * 2019-02-28 2024-09-13 雅祥生技医药股份有限公司 重组蛋白用于治疗代谢疾病
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
CN113735960B (zh) * 2021-03-12 2023-04-28 江南大学 一种fgf重组蛋白治疗nash的应用
CN117486996B (zh) * 2023-12-21 2024-03-19 朗肽生物制药股份有限公司 一种改构的重组人酸性成纤维细胞生长因子的制备及其在皮肤修复中的应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
DE3750197D1 (de) 1986-04-22 1994-08-18 Salk Inst For Biological Studi Antagonisten des Fibroblasten-Wachstumsfaktors.
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH04164096A (ja) * 1989-09-29 1992-06-09 Takeda Chem Ind Ltd ａＦＧＦムテイン，ＤＮＡおよびその用途
EP0420222A1 (de) 1989-09-29 1991-04-03 Takeda Chemical Industries, Ltd. Saure FGF Muteine, und dessen Herstellung
US5478804A (en) 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DE4132005A1 (de) 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
TW275068B (de) 1993-09-24 1996-05-01 American Cyanamid Co
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6326484B1 (en) 1998-05-14 2001-12-04 The Salk Institute For Biological Studies Nucleic acids encoding regulators of FGF-2 transcription (RFT) and variants thereof
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
SI1370260T1 (sl) * 2001-02-20 2011-02-28 Chugai Pharmaceutical Co Ltd Azoli kot inhibitorji malonil-CoA dekarboksilaze, uporabni kot metabolični modulatorji
US20030008820A1 (en) * 2001-03-27 2003-01-09 Massachusetts Institute Of Technology Methods and products related to FGF dimerization
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
US7081489B2 (en) 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
US6982170B1 (en) 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
WO2004003179A1 (en) 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
WO2004064751A2 (en) 2003-01-16 2004-08-05 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
GB0307233D0 (en) * 2003-03-28 2003-04-30 Medical Res Council Improvements in biosensor electrodes
BRPI0410844A (pt) 2003-06-05 2006-06-27 Centelion fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
BRPI0416683A (pt) 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
JP2007536909A (ja) 2003-12-29 2007-12-20 センテリオン 冠動脈または末梢性虚血の治療
US20090111742A1 (en) 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
ATE444306T1 (de) 2004-05-13 2009-10-15 Lilly Co Eli Fgf-21-fusionsproteine
US20080260851A1 (en) 2004-05-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Polymeric Nanoparticles and Nanogels for Extraction and Release of Compounds
ATE513823T1 (de) 2004-08-17 2011-07-15 Simpson Biotech Co Ltd Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP4809352B2 (ja) 2004-09-02 2011-11-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
ATE382337T1 (de) 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
EP1906985A4 (de) 2005-05-10 2012-07-11 Naomi Balaban Zusammensetzungen zur verabreichung von rnaiii-hemmenden peptiden
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007081419A2 (en) 2005-10-17 2007-07-19 The Regents Of The University Of California Compositions and methods related to anti-fgf agents
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CA2664921A1 (en) 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
US20100143330A1 (en) 2006-10-16 2010-06-10 Unversidadde Salamanca (O.T.R.I.) Methods of treating disorders associated with fat storage
US7696171B1 (en) * 2006-11-09 2010-04-13 The Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
WO2008092019A1 (en) 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
ES2665996T3 (es) 2007-04-02 2018-04-30 Genentech, Inc. Anticuerpo agonista de klotho-beta para utilizar en el tratamiento de diabetes mellitus o resistencia a la insulina
JP5187837B2 (ja) 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
US20080260703A1 (en) 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2009048119A1 (ja) 2007-10-12 2009-04-16 National Institute Of Advanced Industrial Science And Technology 高機能化キメラ蛋白質を含有する医薬組成物
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US7956033B2 (en) * 2008-06-10 2011-06-07 Eu Sol Biotech Co., Ltd. Modified peptide of human acidic fibroblast growth factor
US20110300129A1 (en) 2008-12-15 2011-12-08 University Of Rochester Systems and methods for enhancing vaccine efficacy
MX2011007544A (es) 2009-01-23 2011-08-12 Novo Nordisk As Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
UY32607A (es) 2009-05-05 2010-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
CA2764835A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
EP2488643A4 (de) 2009-10-15 2013-07-03 Hoffmann La Roche Chimäre fibroblastwachstumsfaktoren mit veränderter rezeptorspezifizität
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
EP2506861A1 (de) 2009-12-02 2012-10-10 Amgen Inc. Bindeproteine zur bindung von humanem fgfr1c, humanem b-klotho sowie humanem fgfr1c als auch humanem b-klotho
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
CA2796459C (en) * 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
CN102464712A (zh) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 缺失型人成纤维细胞生长因子21变异体及其偶联物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
PL2726511T3 (pl) * 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
US20130033131A1 (en) * 2011-08-04 2013-02-07 Atlantic Industries, Inc. Inductive Energy Converter
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
US8772460B2 (en) 2011-12-16 2014-07-08 Wisconsin Alumni Research Foundation Thermostable FGF-2 mutant having enhanced stability
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
MX2016005101A (es) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
WO2015061351A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
CN106456714A (zh) 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US20180265558A1 (en) 2014-12-03 2018-09-20 Florida State University Research Foundation, Inc. Modified fibroblast growth factor 1 (fgf-1) polypeptides with increased binding affinity for heparin and associated methods
WO2016172156A2 (en) 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
WO2016172153A2 (en) 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
WO2016172290A1 (en) 2015-04-21 2016-10-27 Salk Institute For Biological Studies Methods of treating lipodystrophy using fgf-1 compounds

Also Published As

Publication number Publication date
US20150111821A1 (en) 2015-04-23
MX2016005101A (es) 2017-01-09
AU2014340241A1 (en) 2016-06-02
US20180193418A1 (en) 2018-07-12
WO2015061361A1 (en) 2015-04-30
CN105828833A (zh) 2016-08-03
US9925241B2 (en) 2018-03-27
US20190192630A1 (en) 2019-06-27
EP3060238A4 (de) 2017-06-07
EP3060238A1 (de) 2016-08-31
JP2016535087A (ja) 2016-11-10
JP6621752B2 (ja) 2019-12-18
AU2019200266A1 (en) 2019-02-07
AU2014340241B2 (en) 2018-11-01
CA2928135A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
SG11201603134XA (en) Mutated fibroblast growth factor (fgf) 1 and methods of use
HK1211607A1 (en) Chimeric fibroblast growth factor 21 proteins and methods of use 21
HK1221460A1 (zh) 纖維母細胞生長因子受體抑制劑
HK1223975A1 (zh) 含納米氣泡的組合物及其用途
SI3013769T1 (sl) Ognjevarna formulacija in njena uporaba
IL239766A0 (en) An object made of layered artificial stone
GB201317286D0 (en) Composition and Use
LT3368571T (lt) Į transformuojantį augimo faktorių beta atsaką sukuriantys polipeptidai ir jų panaudojimo būdai
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
HK1224179A1 (zh) 針對成纖維細胞生長因子受體- 的化合物和治療方法
HK1218247A1 (zh) 益生菌和使用方法
EP3043805A4 (de) Biologische prothese sowie verfahren zur herstellung und verwendung
GB201301979D0 (en) New composition and use thereof
EP3068874A4 (de) Fibroblastenmischungen und verfahren zur herstellung und verwendung davon
EP2946016A4 (de) Adenoviren und deren verwendung
SG11201601263WA (en) Recombinant microorganisms and methods of use thereof
HK1194912A2 (en) Growth factor concentrate and the use thereof
EP3055324A4 (de) Modifizierte saure fibroblastenwachstumsfaktoren und zusammensetzung daraus
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same
HK1213573A1 (zh) 基因突變體及其應用
GB201322467D0 (en) Composition and use
GB201310678D0 (en) Surgical tables and methods of operating the same